VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer
Clinical trial NCT05489731 · UNKNOWN
Trial details
- NCT number
- NCT05489731
- Sponsor
- Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-21
- Primary completion
- 2024-02-24
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.